NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 239 filers reported holding NEKTAR THERAPEUTICS in Q2 2021. The put-call ratio across all filers is 0.96 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $81,000 | -80.9% | 15,000 | -52.1% | 0.04% | -79.7% |
| Q4 2021 | $423,000 | -24.7% | 31,300 | 0.0% | 0.17% | -30.6% |
| Q3 2021 | $562,000 | +4.7% | 31,300 | 0.0% | 0.25% | +30.5% |
| Q2 2021 | $537,000 | -14.2% | 31,300 | 0.0% | 0.19% | -30.1% |
| Q1 2021 | $626,000 | +17.7% | 31,300 | 0.0% | 0.27% | +24.2% |
| Q4 2020 | $532,000 | +0.8% | 31,300 | -1.6% | 0.22% | -18.9% |
| Q3 2020 | $528,000 | -47.0% | 31,800 | -26.0% | 0.27% | -51.5% |
| Q2 2020 | $996,000 | +29.7% | 43,000 | 0.0% | 0.56% | +11.0% |
| Q1 2020 | $768,000 | -17.2% | 43,000 | 0.0% | 0.50% | -14.6% |
| Q4 2019 | $928,000 | – | 43,000 | – | 0.59% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |